Galectin Therapeutics (GALT) Stock Price, News & Analysis

Company Overview

Galectin Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination. Galectin Therapeutics collaborates with academic institutions and clinical research organizations to advance its programs, conducting trials across the United States and select international sites. The company’s research builds on academic insights into carbohydrate-binding proteins and their role in cellular signaling pathways.

Galectin Therapeutics’ scientific platform is designed to selectively bind and inhibit galectin-3, a protein known to drive fibrosis through the activation of stellate cells and the accumulation of extracellular matrix. Belapectin has received regulatory attention for its potential to address unmet needs in NASH with advanced fibrosis, and the company continues to generate data on safety, efficacy and biomarker effects to support potential registration pathways.

Under the leadership of President and Chief Executive Officer Peter G. Traber, M.D., Galectin Therapeutics aims to translate its proprietary galectin-inhibitor technology into effective treatments for patients with severe fibrotic and oncology disorders. The company remains committed to leveraging its specialized expertise in galectin biology to address challenging disease areas with significant unmet medical need.

Key Stats

• Today's Range: $2.71 to $3.70
• 50-Day Range: $2.08 to $3.12
• 52-Week Range: $2.03 to $7.13
• Volume: 3.80 million shs
• Average Volume: 304,042 shs
• Market Capitalization: $205.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Hold

Galectin Therapeutics Stock Analysis - MarketRank™

Galectin Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 742nd out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Galectin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Galectin Therapeutics has a consensus price target of $11.00, representing about 252.6% upside from its current price of $3.12.

Amount of Analyst Coverage

Galectin Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Galectin Therapeutics are expected to grow in the coming year, from ($0.37) to ($0.33) per share.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.55% of the float of Galectin Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Galectin Therapeutics has a short interest ratio ("days to cover") of 19.71, which indicates bearish sentiment.

Change versus previous month

Short interest in Galectin Therapeutics has recently increased by 4.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galectin Therapeutics does not currently pay a dividend.

Dividend Growth

Galectin Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 4 news articles for Galectin Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Galectin Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Galectin Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,761.00 in company stock.

Percentage Held by Insiders

52.60% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.68% of the stock of Galectin Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GALT
• CIK: 1133416
• Web: www.galectintherapeutics.com
• Phone: (678) 620-3186
• Fax: 770-864-1327
• Employees: 9
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Galectin Therapeutics: $11.00
• High Price Target: $11.00
• Low Price Target: $11.00
• Potential Upside/Downside: +252.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -164.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.15
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.99) per share
• Price / Book: -1.57

Miscellaneous

• Outstanding Shares: 65,860,000
• Free Float: 31,216,000
• Market Cap: $205.48 million
• Optionable: Optionable
• Beta: 0.47